Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Laura Mauri

Showing results (131-140 of 335) with videos related to

Pageof 34
Sort By:
JACC. Cardiovascular Interventions|February 5, 2010
Long-term clinical and economic analysis of the Endeavor drug-eluting stent versus the Driver bare-metal stent: 4-year results from the ENDEAVOR II trial (Randomized Controlled Trial to Evaluate the Safety and Efficacy of the Medtronic AVE ABT-578 Eluting Driver Coronary Stent in De Novo Native Coronary Artery Lesions)Eric L Eisenstein, William Wijns, Jean Fajadet, et al.
The International Journal of Biochemistry & Cell Biology|February 26, 2022
Galactocerebrosidase deficiency induces an increase in lactosylceramide content: A new hallmark of Krabbe disease?Nadia Papini, Chiara Giallanza, Loredana Brioschi, et al.
Journal of the American College of Cardiology|April 6, 2016
DAPT Score Utility for Risk Prediction in Patients With or Without Previous Myocardial InfarctionDean J Kereiakes, Robert W Yeh, Joseph M Massaro, et al.
JACC. Cardiovascular Interventions|May 21, 2011
Late-term clinical outcomes with zotarolimus- and sirolimus-eluting stents. 5-year follow-up of the ENDEAVOR III (A Randomized Controlled Trial of the Medtronic Endeavor Drug [ABT-578] Eluting Coronary Stent System Versus the Cypher Sirolimus-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions)David E Kandzari, Laura Mauri, Jeffrey J Popma, et al.
Journal of the American College of Cardiology|October 28, 2017
Lesion Complexity and Outcomes of Extended Dual Antiplatelet Therapy After Percutaneous Coronary InterventionRobert W Yeh, Dean J Kereiakes, P Gabriel Steg, et al.
Journal of Neurochemistry|March 16, 2026
Neurotrophic Modulation Restores Motor and Developmental Defects in Zebrafish Models of ints11 DeficiencyAnna Pistocchi, Elena Chiricozzi, Matilde Molteni, et al.
Glycoconjugate Journal|March 26, 2003
Structure of the main ganglioside from the brain of Xenopus laevisAngela Maria Rizzo, Bruno Berra, Federica Rossi, et al.
JACC. Cardiovascular Interventions|June 23, 2009
Impact of target lesion and nontarget lesion cardiac events on 5-year clinical outcomes after sirolimus-eluting or bare-metal stentingRiya Chacko, Meredith Mulhearn, Victor Novack, et al.
JACC. Cardiovascular Interventions|October 23, 2010
Improved late clinical safety with zotarolimus-eluting stents compared with paclitaxel-eluting stents in patients with de novo coronary lesions: 3-year follow-up from the ENDEAVOR IV (Randomized Comparison of Zotarolimus- and Paclitaxel-Eluting Stents in Patients With Coronary Artery Disease) trialMartin B Leon, Eugenia Nikolsky, Donald E Cutlip, et al.
Eurointervention : Journal of Europcr in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology|July 5, 2018
Will SPYRAL HTN-OFF MED change my practice? SPYRAL HTN-OFF MED: a prospective, randomised, sham-controlled trial on renal denervation in the absence of antihypertensive medicationsLucas Lauder, Sebastian Ewen, Michel Azizi, et al.
Pageof 34

Showing results (131-140 of 335) with videos related to

Sort By:
Pageof 34
JACC. Cardiovascular Interventions|February 5, 2010
Long-term clinical and economic analysis of the Endeavor drug-eluting stent versus the Driver bare-metal stent: 4-year results from the ENDEAVOR II trial (Randomized Controlled Trial to Evaluate the Safety and Efficacy of the Medtronic AVE ABT-578 Eluting Driver Coronary Stent in De Novo Native Coronary Artery Lesions)Eric L Eisenstein, William Wijns, Jean Fajadet, et al.
The International Journal of Biochemistry & Cell Biology|February 26, 2022
Galactocerebrosidase deficiency induces an increase in lactosylceramide content: A new hallmark of Krabbe disease?Nadia Papini, Chiara Giallanza, Loredana Brioschi, et al.
Journal of the American College of Cardiology|April 6, 2016
DAPT Score Utility for Risk Prediction in Patients With or Without Previous Myocardial InfarctionDean J Kereiakes, Robert W Yeh, Joseph M Massaro, et al.
JACC. Cardiovascular Interventions|May 21, 2011
Late-term clinical outcomes with zotarolimus- and sirolimus-eluting stents. 5-year follow-up of the ENDEAVOR III (A Randomized Controlled Trial of the Medtronic Endeavor Drug [ABT-578] Eluting Coronary Stent System Versus the Cypher Sirolimus-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions)David E Kandzari, Laura Mauri, Jeffrey J Popma, et al.
Journal of the American College of Cardiology|October 28, 2017
Lesion Complexity and Outcomes of Extended Dual Antiplatelet Therapy After Percutaneous Coronary InterventionRobert W Yeh, Dean J Kereiakes, P Gabriel Steg, et al.
Journal of Neurochemistry|March 16, 2026
Neurotrophic Modulation Restores Motor and Developmental Defects in Zebrafish Models of ints11 DeficiencyAnna Pistocchi, Elena Chiricozzi, Matilde Molteni, et al.
Glycoconjugate Journal|March 26, 2003
Structure of the main ganglioside from the brain of Xenopus laevisAngela Maria Rizzo, Bruno Berra, Federica Rossi, et al.
JACC. Cardiovascular Interventions|June 23, 2009
Impact of target lesion and nontarget lesion cardiac events on 5-year clinical outcomes after sirolimus-eluting or bare-metal stentingRiya Chacko, Meredith Mulhearn, Victor Novack, et al.
JACC. Cardiovascular Interventions|October 23, 2010
Improved late clinical safety with zotarolimus-eluting stents compared with paclitaxel-eluting stents in patients with de novo coronary lesions: 3-year follow-up from the ENDEAVOR IV (Randomized Comparison of Zotarolimus- and Paclitaxel-Eluting Stents in Patients With Coronary Artery Disease) trialMartin B Leon, Eugenia Nikolsky, Donald E Cutlip, et al.
Eurointervention : Journal of Europcr in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology|July 5, 2018
Will SPYRAL HTN-OFF MED change my practice? SPYRAL HTN-OFF MED: a prospective, randomised, sham-controlled trial on renal denervation in the absence of antihypertensive medicationsLucas Lauder, Sebastian Ewen, Michel Azizi, et al.
Pageof 34